ScripWho: Kymera Therapeutics with Gilead Sciences What: On June 25, Kymera announced a deal with Gilead for molecular glue degraders targeting CDK2. Why: While potent anti-cancer drugs, traditional C
Pink SheetBiotechnology Innovation Organization CEO John Crowley is feeling more optimistic about the state of the US Food and Drug Administration because the uncertainty of the early days of the Trump Administ
ScripNektar Therapeutics is making Phase III preparations for rezpegaldesleukin, also known as rezpeg, after the potential pipeline-in-a-product hit its main goal in a mid-stage trial for patients with ato
ScripNovo Nordisk’s Wegovy (injectable semaglutide) has made its India debut, setting the stage for a tight battle with rival Eli Lilly’s Mounjaro (tirzepatide) in a market where an estimated 254 million p